Indwelling catheters and medical implants with FXIIIa inhibitors: a novel approach to the treatment of catheter and medical device-related infections

Nooshin Daneshpour, Russell Collighan, Yvonne Perrie, Peter Lambert, Dan Rathbone, Deborah Lowry, Martin Griffin

Research output: Contribution to journalArticle

Abstract

Central venous catheters (CVCs) are being utilized with increasing frequency in intensive care and general medical wards. In spite of the extensive experience gained in their application, CVCs are related to the long-term risks of catheter sheath formation, infection, and thrombosis (of the catheter or vessel itself) during catheterization. Such CVC-related-complications are associated with increased morbidity, mortality, duration of hospitalization, and medical care cost [1]. The present study incorporates a novel group of Factor XIIIa (FXIIIa, plasma transglutaminase) inhibitors into a lubricious silicone elastomer in order to generate an optimized drug delivery system whereby a secondary sustained drug release profile occurs following an initial burst release for catheters and other medical devices. We propose that the incorporation of FXIIIa inhibitors into catheters, stents, and other medical implant devices would reduce the incidence of catheter sheath formation, thrombotic occlusion, and associated staphylococcal infection. This technique could be used as a local delivery system for extended release with an immediate onset of action for other poorly aqueous soluble compounds. © 2012 Elsevier B.V. All rights reserved.
LanguageEnglish
Pages106–113
Number of pages8
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume83
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Indwelling Catheters
Catheters
Central Venous Catheters
Equipment and Supplies
Factor XIIIa
Infection
Therapeutics
Staphylococcal Infections
Silicone Elastomers
Patients' Rooms
Drug Delivery Systems
Critical Care
Catheterization
Health Care Costs
Stents
Hospitalization
Thrombosis
Morbidity
Mortality
Incidence

Cite this

@article{3809f879f5e644b682b5873a98d6a307,
title = "Indwelling catheters and medical implants with FXIIIa inhibitors: a novel approach to the treatment of catheter and medical device-related infections",
abstract = "Central venous catheters (CVCs) are being utilized with increasing frequency in intensive care and general medical wards. In spite of the extensive experience gained in their application, CVCs are related to the long-term risks of catheter sheath formation, infection, and thrombosis (of the catheter or vessel itself) during catheterization. Such CVC-related-complications are associated with increased morbidity, mortality, duration of hospitalization, and medical care cost [1]. The present study incorporates a novel group of Factor XIIIa (FXIIIa, plasma transglutaminase) inhibitors into a lubricious silicone elastomer in order to generate an optimized drug delivery system whereby a secondary sustained drug release profile occurs following an initial burst release for catheters and other medical devices. We propose that the incorporation of FXIIIa inhibitors into catheters, stents, and other medical implant devices would reduce the incidence of catheter sheath formation, thrombotic occlusion, and associated staphylococcal infection. This technique could be used as a local delivery system for extended release with an immediate onset of action for other poorly aqueous soluble compounds. {\circledC} 2012 Elsevier B.V. All rights reserved.",
author = "Nooshin Daneshpour and Russell Collighan and Yvonne Perrie and Peter Lambert and Dan Rathbone and Deborah Lowry and Martin Griffin",
note = "Copyright {\circledC} 2012. Published by Elsevier B.V.",
year = "2013",
month = "1",
doi = "10.1016/j.ejpb.2012.09.005",
language = "English",
volume = "83",
pages = "106–113",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Indwelling catheters and medical implants with FXIIIa inhibitors

T2 - European Journal of Pharmaceutics and Biopharmaceutics

AU - Daneshpour, Nooshin

AU - Collighan, Russell

AU - Perrie, Yvonne

AU - Lambert, Peter

AU - Rathbone, Dan

AU - Lowry, Deborah

AU - Griffin, Martin

N1 - Copyright © 2012. Published by Elsevier B.V.

PY - 2013/1

Y1 - 2013/1

N2 - Central venous catheters (CVCs) are being utilized with increasing frequency in intensive care and general medical wards. In spite of the extensive experience gained in their application, CVCs are related to the long-term risks of catheter sheath formation, infection, and thrombosis (of the catheter or vessel itself) during catheterization. Such CVC-related-complications are associated with increased morbidity, mortality, duration of hospitalization, and medical care cost [1]. The present study incorporates a novel group of Factor XIIIa (FXIIIa, plasma transglutaminase) inhibitors into a lubricious silicone elastomer in order to generate an optimized drug delivery system whereby a secondary sustained drug release profile occurs following an initial burst release for catheters and other medical devices. We propose that the incorporation of FXIIIa inhibitors into catheters, stents, and other medical implant devices would reduce the incidence of catheter sheath formation, thrombotic occlusion, and associated staphylococcal infection. This technique could be used as a local delivery system for extended release with an immediate onset of action for other poorly aqueous soluble compounds. © 2012 Elsevier B.V. All rights reserved.

AB - Central venous catheters (CVCs) are being utilized with increasing frequency in intensive care and general medical wards. In spite of the extensive experience gained in their application, CVCs are related to the long-term risks of catheter sheath formation, infection, and thrombosis (of the catheter or vessel itself) during catheterization. Such CVC-related-complications are associated with increased morbidity, mortality, duration of hospitalization, and medical care cost [1]. The present study incorporates a novel group of Factor XIIIa (FXIIIa, plasma transglutaminase) inhibitors into a lubricious silicone elastomer in order to generate an optimized drug delivery system whereby a secondary sustained drug release profile occurs following an initial burst release for catheters and other medical devices. We propose that the incorporation of FXIIIa inhibitors into catheters, stents, and other medical implant devices would reduce the incidence of catheter sheath formation, thrombotic occlusion, and associated staphylococcal infection. This technique could be used as a local delivery system for extended release with an immediate onset of action for other poorly aqueous soluble compounds. © 2012 Elsevier B.V. All rights reserved.

UR - http://www.scopus.com/inward/record.url?scp=84871918803&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2012.09.005

DO - 10.1016/j.ejpb.2012.09.005

M3 - Article

VL - 83

SP - 106

EP - 113

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 1

ER -